MCUR +50% bounce today from yesterday’s 78% sell-off. This is now a stock for mindless daytrading until data from the second phase-3 trial are reported in 4Q15.
The second phase-3 was in diabetic foot ulcers; the first phase-3, which also failed, was in venous leg ulcers (#msg-116348664).
All MCUR has left is its cash—about $30M as of 9/30/15. It is now a plausible reverse-merger candidate for a private company who wants to go public via the back door.
Market Data 
Markets 
AI
